New Modalities in Neurodegenerative Disease Management: Is Europe Ready to Innovate?
Early diagnosis of Alzheimer’s and Parkinson’s diseases remains a critical challenge in Europe. Current methods are often invasive, slow, and costly, delaying much-needed interventions. However, new blood-based diagnostics, AI-driven cognitive assessments, and innovative treatments are reshaping the landscape of neurodegenerative disease care.
This seminar brings together leading experts from academia, policy, and industry to discuss the future of diagnosis and care in Europe, along with the regulatory frameworks needed to support this transformation.
Seminar Highlights:
13:00 – 14:00 | Keynote Presentations
- Prof. Mart SAARMA, Neuroscientist | President of the Estonian Academy of Sciences/ Senior Partner / CSO / Member of the Board of Directors | GeneCode – “Development of Novel Drugs for Disease-Modifying Treatment of Parkinson’s Disease”
- Prof. Toomas TOOMSOO, Neurologist | Confido Medical Centre – Centre for Parkinson’s disease and other movement disorders/Professor of Neurology | Tallinn University – “Discovered Today, Treated Tomorrow: Future Medicine Transforming Neurodegenerative Disease Care
14:00 – 15:30 | Panel 1: New Opportunities in Diagnosis and Care
Discussing the impact of AI, digital diagnostics, and the European Health Data Space (EHDS)
16:30 – 17:30 | Panel 2: Technological and Regulatory Challenges
Exploring Europe’s preparedness for innovation, including ethical AI use, data sharing, and implementation of the AI Act.
The event will conclude with a networking reception (17:45–18:30), offering the opportunity to connect with leading voices from research, healthcare, technology, and policymaking.
Note: Entry upon for registered participants with ID card/passport only.